



MannKind Corporation to Participate in the BTIG Biotechnology Conference

August 1, 2022

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- **MannKind Corporation (Nasdaq: MNKD)**, a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Steven Binder will participate in the BTIG Biotechnology Conference taking place on Monday, August 8 – Tuesday, August 9, 2022.

This conference is being hosted by BTIG, a global financial services firm specializing in institutional trading, investment banking, research, and related brokerage services. BTIG's Corporate Access program hosts client events across the consumer, digital assets, energy and infrastructure, financials, healthcare, real estate, and technology sectors.

Management will be participating in one-on-one meetings throughout the event. To join the conference and arrange a meeting with management, please email info@btig.com.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of therapeutic and convenient products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza[®] (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company's partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Contact:

Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com



Source: MannKind